Visus Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for Treatment of Presbyopia

Visus Therapeutics has revealed positive topline results from VIVID, the company’s Phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia.

Visus Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for Treatment of Presbyopia
December 01, 2021
Nicox Announces Positive Post Hoc Results from its Clinical Trial for Dry Eye Treatment

Nicox SA revealed positive post-hoc data from its Mississippi Phase 2b clinical trial, finding that once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, is beneficial in alleviating dry eye symptoms in a subgroup of patients.

Nicox Announces Positive Post Hoc Results from its Clinical Trial for Dry Eye Treatment
December 02, 2021
Kiora: KIO-101 Eye Drop is Safe and Tolerable for Dry Eye Disease

Kiora Pharmaceuticals revealed topline data from its vehicle-controlled, randomized safety study of KIO-101 eye drops.

Kiora: KIO-101 Eye Drop is Safe and Tolerable for Dry Eye Disease
December 15, 2021
Nanodropper to Donate 1,000 Nanodropper Adaptors to Support Global Access to Eye Care

Nanodropper launched its "2022 Give the Gift of Vision" program, which aims to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its international nonprofit partners.

Nanodropper to Donate 1,000 Nanodropper Adaptors to Support Global Access to Eye Care
October 26, 2022
Salvat Laboratories Submits NDA for First Ocular Corticosteroid Nanoemulsion

Salvat Laboratories has submitted the NDA documentation for a new drug application to the FDA for approval of Clobetasol, the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in patients undergoing eye surgery.

Salvat Laboratories Submits NDA for First Ocular Corticosteroid Nanoemulsion
November 03, 2022
High-tech Eye Drop Aims to Treat Corneal Neovascularisation

New study has paved the way for a long-lasting eye drop to treat corneal neovascularization (CoNV), a disease that affects over a million individuals worldwide every year.

High-tech Eye Drop Aims to Treat Corneal Neovascularisation
January 27, 2022
Théa Launches iVIZIA OTC Eye Care Products in US

Théa Pharma announced the availability of the iVIZIA line of over-the-counter (OTC) eye care products in the United States. The iVIZIA OTC product line includes lubricating eye drops, lubricating eye gel, and three options for daily hygiene of sensitive e

Théa Launches iVIZIA OTC Eye Care Products in US
April 25, 2022
More